For women under the age of 40, new rules limit the use of the Oxford-AstraZeneca vaccine.
The Ministry of National Health Services has released new rules for Covid-19 vaccinations, limiting the use of the Oxford-AstraZeneca vaccine to women under the age of 40.
The vaccine is also not recommended for anyone under the age of 18; people with a history of severe allergic reactions to any of its components (e.g. polysorbate); patients with active Covid-19; people who developed clotting disorder after receiving the first dose of AstraZeneca vaccine; and people who have a fever before receiving a vaccination shot.
Individuals on short-term immunosuppressive treatment have also been requested to wait 28 days after their prescription has ended before getting vaccinated.
The AstraZeneca vaccine, on the other hand, is suggested for all male individuals over the age of 18; all persons over the age of 40, regardless of gender; and those with diabetes, hypertension, heart disease, or other stable chronic diseases.
Two doses of the vaccine will be administered 12 weeks apart.
On Saturday, 1.23 million doses of the AstraZeneca vaccine were sent to the nation as part of the World Health Organization’s COVAX initiative.
A shipment of 1 million SinoVac doses arrived in the nation on Sunday, according to the NCOC, the united government effort against the pandemic. Another batch of 1 million doses will arrive between May 13-15, according to the NCOC.
The government is acquiring vaccine to supplement a countrywide immunization program that began in the first week of February. China has provided 10.19 million doses of several vaccines – Sinopharm, SinoVac, and CanSino – thus far.